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Abstract
Background: We previously reported on the positive association of hemoglobin with hypertension and
atherosclerosis. On the other hand, hepatocyte growth factor (HGF) has been evaluated as a possible biochemical
index of hypertension-induced vascular damage. However, no studies have reported on a correlation between
hemoglobin and HGF accounting for hypertension status.
Methods: A cross-sectional study of 1108 subjects (392 men and 716 women, 40–93 years old) who were
undergoing a general checkup in 2014 was conducted.
Results: Multiple linear regression analysis adjustment for known cardiovascular risk factors showed no significant
correlation between hemoglobin and HGF in non-hypertensive subjects, but a significant positive correlation in
hypertensive subjects; β (parameter estimate) = 0.3 (p = 0.975) for non-hypertensive men, β = 0.4 (p = 0.925) for non-
hypertensive women, β = 32.7 (p < 0.001) for hypertensive men, and β = 18.7 (p = 0.002) for hypertensive women.
Conclusion: We found a significant positive correlation between hemoglobin and HGF among hypertensive men
and women. Like HGF, hemoglobin may be a useful indicator to evaluate hypertension-induced vascular damage.
Since hemoglobin can easily be measured, these results support hemoglobin as an efficient tool to evaluate
vascular damage induced by hypertension in daily medical practice.
Background
We reported independent positive associations of
hemoglobin level with hypertension [1] and atheroscler-
osis [2] in both men and women. On the other hand,
endothelial dysfunction may contribute to the increased
vascular tone seen with hypertension [3]. Hemoglobin
might therefore serve as an indicator of vascular damage
induced by hypertension. Hepatocyte growth factor
(HGF), which is known as an angiogenic growth factor
[4, 5], plays an important role in endothelial mainten-
ance (vascular maintenance) and endothelial repair
(vascular repair). HGF prevents apoptosis of endothelial
cells [6, 7] and suppresses xanthin oxidase activation [8]
induced by hypoxia/reoxygenation. Furthermore, HGF
promotes endothelial cell differentiation and increases
endothelial progenitor cell migration and proliferation
[9]. However, other studies have reported HGF as a pos-
sible biochemical index of vascular damage due to
hypertension [4, 10–14]. Another study reported a sig-
nificant correlation between increased HGF concentra-
tion and carotid atherosclerosis [15]. These studies
indicate that high plasma concentration of HGF indi-
cates the presence of aggressive vascular remodeling,
which results in atherosclerosis. Since HGF is constitu-
tively produced by human bone marrow and indirectly
promotes the growth of undifferentiated hematopoietic
cells and erythroid progenitor cells [16], HGF level
should correlate with hemoglobin, particularly when
the bone marrow becomes activated by hypertension.
Hemoglobin is an easily measured parameter; there-
fore, if it can substitute for HGF as a possible bio-
chemical index of vascular damage due to hypertension
[4, 10–14], it could serve as an efficient tool for blood
pressure control in daily medical practice. Since the preva-
lence of hypertension might play an important role as a
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vascular impairment factor, the correlation between
hemoglobin and HGF should account for hyperten-
sion status. However, no studies have reported a cor-
relation between hemoglobin and HGF accounting for
hypertension status. We therefore hypothesized that
non-hypertensive men and women would show no
significant correlation between hemoglobin and HGF,
whereas a significant correlation would be found in
subjects with hypertension.
To investigate these possible correlations, we conducted
a cross-sectional study of 1108 subjects (392 men and 716




The study was conducted during a medical screening
program for members of the general population aged
40–99 years who were living in Goto city, Nagasaki
Prefecture, Japan. After obtaining informed consent,
1555 Japanese subjects (536 men and 1019 women) were
enrolled. Subjects without habitual status (drinking,
smoking) data (1 male, 1 female) and/or without blood
sample data (143 males, 301 females) were excluded. To
avoid the influence of abnormal HGF values, one woman
with extremely high HGF (4825 pg/mL) was excluded,
leaving a total of 1108 subjects (392 men, 716 women)
participating in the study. This study was approved by
the Ethics Committee for Human Use of Nagasaki
University (project registration number 14051404).
Data collection and laboratory measurements
Systolic and diastolic blood pressures at rest in a sitting
position were recorded using a blood pressure measur-
ing device (HEM-907; Omron, Kyoto, Japan) by trained
technicians.
Height and weight in bare feet and light clothing were
measured, and body mass index (BMI) was calculated as
weight (kg)/(height (m))2. Trained interviewers obtained
information on smoking and drinking status. Fasting
blood samples were collected in an EDTA-2K tube and a
siliconized tube. Samples from the siliconized tube were
centrifuged after blood coagulation, and the separated
serum was collected. Samples from the EDTA-2K tube
were used to measure hemoglobin using the sodium lauryl
surfate (SLS)-hemoglobin method at SRL, Inc. (Tokyo,
Japan). This method is recommended by the International
Committee for Standardization in hematology. Serum tri-
glyceride (TG), serum high-density lipoprotein (HDL)
cholesterol, serum low-density lipoprotein (LDL) chol-
esterol, serum aspartate aminotransferase (AST), serum
γ-glutamyltranspeptidase (γ-GTP), hemoglobin (Hb)A1C,
and serum creatinine were measured using standard
laboratory procedures at SRL, Inc. (Tokyo, Japan). To
measure HGF, serum samples were diluted fourfold
with specific Bio-Plex sample diluents. HGF concentration
was determined using a fluorescent bead-based immuno-
sorbent assay on a suspension array. Glomerular filtra-
tion rate (GFR) was estimated using an established
method with three variations that were recently pro-
posed by a working group of the Japanese Chronic
Kidney Disease Initiative [17]. According to this adap-
tation, GFR (mL/min/1.73 m2) = 194 × (serum creatinine
(enzyme method))−1.094 × (age)−0.287 × (0.739 for women).
Hypertension was defined as a systolic blood pressure
≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg.
Statistical analysis
Sex-specific models were conducted. Difference in
mean ± standard deviation (SD) values, the prevalence
of potential confounding factors, and p values by
hypertension status were calculated. Simple correl-
ation coefficients of HGF and other variables stratified
by hypertension were calculated. Simple and multiple
linear regression analyses stratified by hypertension
were performed to evaluate the correlation between
hemoglobin and HGF. Probability values less than
0.05 were considered to indicate statistical significance.
All statistical analyses were performed with the SAS sys-
tem for Windows (version 9.3; SAS Inc., Cary, NC).
Results
Among the study population, 512 individuals (198 men
and 314 women) were recognized as having hyperten-
sion. Sex-specific characteristics of the study population
by hypertension status are shown in Table 1. Both men
and women subjects with hypertension showed signifi-
cantly higher levels of hemoglobin and BMI than sub-
jects without hypertension. The mean ± SD values of
hemoglobin and BMI for non-hypertensive and hyper-
tensive men were 14.5 ± 1.3 g/dL, 22.7 ± 2.7 kg/m2 and
14.7 ± 1.2 g/dL, 23.7 ± 3.1 kg/m2 (p = 0.025 and p < 0.001),
respectively; and the corresponding values for non-
hypertensive and hypertensive women were 12.9 ± 1.1 g/dL,
22.3 ± 3.5 kg/m2 and 13.2 ± 1.2 g/dL, 23.1 ± 3.3 kg/m2
(p = 0.003 and p = 0.004), respectively.
The simple correlation coefficients of HGF and other
variables stratified by hypertension status are shown in
Table 2. In non-hypertensive men and women, no sig-
nificant correlation between hemoglobin and HGF was
seen, whereas a significant positive correlation was seen
among subjects with hypertension. This was also seen
from simple linear regression analysis (Fig. 1). From
multiple linear regression analysis adjustment for known
cardiovascular risk factors, significant positive correl-
ation between hemoglobin and HGF was observed in
both men (β (parameter estimate) = 32.7, p < 0.001) and
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women (β = 18.7, p = 0.002) with hypertension (Tables 3
and 4).
Discussion
A major finding of this study was a significant positive
correlation between hemoglobin and HGF among
hypertensive men and women subjects, but not among
non-hypertensive subjects.
The association between hypertension and endothelial
dysfunction is bidirectional. In a state of hypertension,
oxidative stress increases due to increased NADH/
NADPH oxidase activation, while oxidative stress
Table 1 Sex-specific characteristics of the study population by hypertension status
Men Women
Hypertension Hypertension
(−) (+) p (−) (+) p
No. of cases 194 198 402 314
Age 69.4 ± 9.4 69.9 ± 9.1 0.612 67.3 ± 9.7 72.9 ± 8.9 <0.001
Hepatocyte growth factor (HGF), pg/mL 279.7 ± 126.8 284.6 ± 150.9 0.730 239.6 ± 88.7 256.1 ± 119.8 0.035
Hemoglobin (Hb), g/dL 14.5 ± 1.3 14.7 ± 1.2 0.025 12.9 ± 1.1 13.2 ± 1.2 0.003
Systolic blood pressure, mmHg 123 ± 10 151 ± 13 <0.001 124 ± 10 153 ± 14 <0.001
Diastolic blood pressure, mmHg 76 ± 9 91 ± 10 <0.001 74 ± 9 86 ± 11 <0.001
Body mass index (BMI), kg/m2 22.7 ± 2.7 23.7 ± 3.1 <0.001 22.3 ± 3.5 23.1 ± 3.3 0.004
Curent drinker, % 53.1 63.6 0.034 17.7 14.0 0.188
Curent smoker, % 16.5 18.2 0.660 3.7 1.6 0.085
Serum HDL cholesterol, mg/dL 56 ± 15 57 ± 14 0.588 63 ± 14 61 ± 14 0.049
Serum LDL cholesterol, mg/dL 109 ± 28 111 ± 29 0.517 120 ± 28 124 ± 29 0.052
Serum triglyceride (TG), mg/dL 108 ± 72 122 ± 111 0.144 99 ± 53 114 ± 62 <0.001
Serum aspartate transaminase (AST), IU/L 25 ± 9 26 ± 11 0.096 22 ± 6 23 ± 7 0.127
Serum γ-glutamyltranspeptidase (γ-GTP), IU/L 34 ± 28 51 ± 79 0.004 23 ± 19 21 ± 14 0.073
Hemoglobin A1c (HbA1c), % 5.6 ± 0.5 5.8 ± 0.9 0.109 5.6 ± 0.4 5.7 ± 0.5 0.137
Glomerular filtration rate (GFR), mL/min/1.73 m2 69.1 ± 15.2 69.4 ± 13.8 0.847 68.8 ± 14.1 66.5 ± 13.6 0.026
Table 2 Sex-specific simple correlation coefficient of hepatocyte growth factor (HGF) and other variables
Men Women
Hypertension (−) Hypertension (+) Hypertension (−) Hypertension (+)
r p r p r p r p
Age 0.11 0.123 −0.16 0.020 0.15 0.003 0.10 0.091
Systolic blood pressure 0.19 0.009 −0.02 0.737 0.07 0.156 −0.02 0.720
Diastolic blood pressure 0.18 0.013 0.08 0.250 −0.06 0.269 0.03 0.589
Body mass index (BMI) 0.03 0.638 0.33 <0.001 0.16 0.001 0.13 0.027
Drinking status −0.03 0.642 −0.01 0.936 −0.06 0.257 0.05 0.370
Smoking status 0.14 0.059 0.12 0.086 −0.004 0.937 0.06 0.301
Serum HDL cholesterol −0.12 0.107 −0.08 0.237 −0.14 0.004 −0.08 0.140
Serum LDL cholesterol −0.07 0.346 −0.09 0.196 −0.07 0.146 −0.10 0.081
Serum triglycerides (TG) 0.04 0.618 0.09 0.187 0.01 0.845 0.04 0.510
Serum aspartate transaminase (AST) 0.01 0.888 0.25 <0.001 0.02 0.647 0.11 0.047
Serum γ-glutamyltranspeptidase (γ-GTP) 0.03 0.705 0.26 <0.001 −0.01 0.834 0.11 0.043
Hemoglobin A1c (HbA1c) 0.11 0.117 0.05 0.507 0.11 0.031 0.17 0.002
Glomerular filtration rate (GFR) −0.04 0.542 0.09 0.223 −0.09 0.074 −0.01 0.869
Hemoglobin (Hb) −0.01 0.905 0.28 <0.001 −0.02 0.636 0.17 0.003
Drinking status (never drinker, former drinker, current drinker (<23 g/week, 23–45 g/week, 46–68 g/week, ≥69 g/week)), smoking status (never smoker, former
smoker, current smoker)



























































































HGF (pg/mL) = -8.5× Hb (g/dL) + 292.1
( p = 0.905 )
HGF (pg/mL) = 33.5× Hb (g/dL) - 209.2
( p < 0.001 )
HGF (pg/mL) = -18.8× Hb (g/dL) + 263.9
( p = 0.636 ) 
HGF (pg/mL) = 16.9× Hb (g/dL) + 33.1
( p = 0.003 )
Fig. 1 Simple linear regression analysis of hepatocyte growth factor (HGF) and with hemoglobin (Hb) in a non-hypertensive men, b hypertensive
men, c non-hypertensive women, and d hypertensive women
Table 3 Multiple linear regression analysis of hepatocyte growth factor (HGF) with relevant factors adjusted for confounding factors
among men
Hypertension (−) Hypertension (+)
β 95 % CI p β 95 % CI p
No. of participants 194 198
Age 1.3 (−0.9, 3.5) 0.255 −0.3 (−3.0, 2.4) 0.815
Systolic blood pressure 0.6 (−1.9, 3.2) 0.620 0.1 (−1.5, 1.7) 0.923
Diastolic blood pressure 2.4 (−0.5, 5.3) 0.110 −1.1 (−3.5, 1.4) 0.396
Body mass index (BMI) −1.7 (−9.5, 6.1) 0.668 11.2 (3.9, 18.5) 0.003
Drinking status −4.0 (−13.8, 5.7) 0.413 −5.5 (−14.8, 3.9) 0.250
Smoking status 25.8 (−3.2, 54.9) 0.081 11.3 (−20.5, 43.2) 0.484
Serum HDL cholesterol −0.9 (−2.4, 0.7) 0.276 −0.4 (−1.9, 1.2) 0.663
Serum LDL cholesterol −0.4 (−1.1, 0.2) 0.195 −0.4 (−1.2, 0.3) 0.259
Serum triglycerides (TG) −0.04 (−0.3, 0.3) 0.800 −0.2 (−0.4, 0.03) 0.091
Serum aspartate aminotransferase (AST) −0.4 (−2.7, 2.0) 0.757 1.6 (−0.7, 3.8) 0.170
Serum γ-glutamyltranspeptidase (γ-GTP) 0.2 (−0.6, 1.0) 0.602 0.4 (0.04, 0.8) 0.029
Hemoglobin A1c (HbA1c) 14.1 (−20.8, 48.9) 0.427 6.5 (−16.8, 29.9) 0.582
Glomerular filtration rate (GFR) 0.1 (−1.2, 1.4) 0.882 0.1 (−1.4, 1.6) 0.906
Hemoglobin (Hb) 0.3 (−15.9, 16.4) 0.975 32.7 (14.4, 51.0) <0.001
Drinking status (never drinker, former drinker, current drinker (<23 g/week, 23–45 g/week, 46–68 g/week, ≥69 g/week)), smoking status (never smoker, former
smoker, current smoker)
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inactivates nitric monoxide (NO), which is known as an
endothelial-dependent vasodilation factor, by causing
injury to endothelial cells, resulting in increased vaso-
constriction [18]. Hypertension is therefore maintained.
In addition to this mechanism, endothelial dysfunc-
tion causes reduced NO production, and increased
endothelial-dependent vasoconstriction factors such as
endothelin, angiotensin II, and thromboxane are also
observed in hypertension [19]. The number of growth
factors in circulating blood was reported to increase
when complications consisting of hypertension arose
in response to vascular endothelial cell damage [20].
Additionally, HGF is reported to be produced by
polynuclear leukocytes [21], vascular smooth muscle
cells, endothelial cells in humans in vivo [22], and human
osteoblasts in vitro [23], and unlike most known growth
factors, HGF acts specifically on the endothelium and
does not promote the growth of smooth muscle cells [5].
Furthermore, one study reported that the overexpression
of HGF in smooth muscle cells can be beneficial for pro-
moting endothelial cell differentiation and increasing
endothelial progenitor cell migration and proliferation [9].
However, human endothelial progenitor cells (CD34-
positive cells) are reported to differentiate into not
only endothelial cells but also into foam cells, which
are a contributing factor in the development of ath-
erosclerosis [24]. Other studies have reported the
presence of CD34-positive cells in human atherosclerotic
lesions [25, 26]. Furthermore, increased HGF concentra-
tion significantly correlates with carotid atherosclerosis
[15]. Therefore, even though HGF has a beneficial effect
on vascular endothelial repair, subjects with a high plasma
HGF concentration likely have a high risk of athero-
sclerosis (endothelial dysfunction). Additionally, HGF
is reported to indirectly promote the growth of undif-
ferentiated hematopoietic cells (CD34-positive cells)
and erythroid progenitor cells (source of hemoglobin)
[16]. Also, because osteoblasts regulate the production
of hematopoietic stem cells in the bone marrow [27, 28],
and HGF is reported to be produced by osteoblasts [23],
high levels of plasma HGF and hemoglobin might also
indicate high activity of the bone marrow. Since
hematopoietic stem cells derived from the bone marrow
play a major role in vascular homeostasis [29–31], and
other studies have reported that hemoglobin plays an im-
portant role in the progression of atherosclerosis [32, 33],
hemoglobin level significantly correlates with HGF when
the bone marrow is activated by endothelial damage
induced by hypertension. In our previous study, we
reported that hemoglobin levels in both men and
women are positively associated with hypertension [1]
and atherosclerosis [2]. Other studies identified HGF
as a possible biochemical index of hypertension-
induced vascular damage [4, 10–14]. These studies
partly support the abovementioned mechanisms. A
possible mechanism underlying the observed correl-
ation between hemoglobin and HGF in hypertensive
subjects is summarized in Fig. 2.
Our findings should be interpreted with some caution.
Although hemoglobin, which might act as a marker of
Table 4 Multiple linear regression analysis of hepatocyte growth factor (HGF) with relevant factors adjusted for confounding factors
among women
Hypertension (−) Hypertension (+)
β 95 % CI p β 95 % CI p
No. of participants 402 314
Age 1.1 (−0.02, 2.2) 0.055 2.6 (0.8, 4.5) 0.006
Systolic blood pressure 0.4 (−0.6, 1.5) 0.418 −0.7 (−1.7, 0.3) 0.181
Diastolic blood pressure −0.5 (−1.7, 0.8) 0.450 0.9 (−0.6, 2.3) 0.231
Body mass index (BMI) 3.7 (1.0, 6.3) 0.007 1.5 (−2.7, 5.8) 0.482
Drinking status −1.8 (−8.0, 4.4) 0.562 4.3 (−6.3, 15.0) 0.426
Smoking status 11.0 (−9.6, 31.6) 0.293 25.2 (−15.2, 65.5) 0.220
Serum HDL cholesterol −0.8 (−1.5,−0.1) 0.023 −1.0 (−2.0, 0.05) 0.061
Serum LDL cholesterol −0.2 (−0.6, 0.1) 0.129 −0.4 (−0.8, 0.1) 0.124
Serum triglycerides (TG) −0.1 (−0.3, 0.04) 0.122 −0.1 (−0.3, 0.2) 0.598
Serum aspartate aminotransferase (AST) −0.3 (−1.9, 1.2) 0.652 1.4 (−0.5, 3.3) 0.146
Serum γ-glutamyltranspeptidase (γ-GTP) 0.05 (−0.4, 0.5) 0.851 0.5 (−0.5, 1.5) 0.353
Hemoglobin A1c (HbA1c) 11.5 (−10.3, 33.4) 0.301 41.7 (16.6, 66.9) 0.001
Glomerular filtration rate (GFR) −0.2 (−0.9, 0.5) 0.627 0.3 (−0.7, 1.4) 0.525
Hemoglobin (Hb) 0.4 (−7.5, 8.3) 0.925 18.7 (6.7, 30.7) 0.002
Drinking status (never drinker, former drinker, current drinker (<23 g/week, 23–45 g/week, 46–68 g/week, ≥69 g/week)), smoking status (never smoker, former
smoker, current smoker)
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bone marrow activity, showed a significant positive
correlation with HGF, we were not able to evaluate the
influence of hematopoietic stem cells. Further investiga-
tions using hematopoietic stem cell data are necessary.
Finally, since this was a cross-sectional study, no causal
relationships were able to be established.
Conclusion
In conclusion, an independent positive correlation be-
tween hemoglobin and HGF was observed in hyper-
tensive Japanese males and females. Since HGF is
useful for evaluating hypertension-induced vascular
damage, hemoglobin may be beneficial in this regard
as well. Since hemoglobin is easily measured, the re-
sults indicate that it could serve as an efficient tool
to evaluate vascular damage induced by hypertension
in daily medical practice.
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